The Food and Drug Administration (FDA) has approved Pfizer’s COVID-19 tablets. This was reported on the company’s website.
According to Pfizer, a drug called Paxlovid could be used to treat mild to moderate coronavirus infections in the body.
“Pfizer is ready to immediately begin shipping the drug to the US to place Paxlovid in the hands of the right patients as soon as possible,” said Pfizer Chairman and Chief Executive Officer Albert Burla.
It is noted that the drug is intended for adults and adolescents aged 12 years and older who are at high risk of disease progression to severe forms, including hospitalization or death.
Side effects from the use of pills include a violation of taste, diarrhea, high blood pressure and muscle pain.
According to research, Paxlovid reduces the risk of hospitalization or death from COVID-19 by 89% (within three days of the onset of symptoms) and by 88% (within five days of the onset of symptoms).
In addition, recent laboratory data show that the drug remains effective against the Omicron strain, Pfizer said.
In November, Pfizer entered into an agreement with the US government to supply 10 million drug treatments due to be completed in 2022, the company said in a statement.
December 16 at the Center. N.F. Gamalei announced the filing of the first patent for the formula of a substance that will actively inhibit the RNA polymerase of the coronavirus. This compound could form the basis of a future drug for COVID-19. At the Center. N.F. The Gamaleys told Izvestia that molecular docking will be used to create a future drug.
Prior to that, on December 14, Deputy Minister of Health Tatyana Semenova said that in addition to vaccines, 14 drugs for COVID-19 were registered in Russia.
A day earlier, it became known that the drug for alcohol dependence disulfiram was also effective in the treatment of COVID-19.
